关键词: 晚期非小细胞肺癌, 清热化痰益气散结方, 抗肿瘤, 基质金属蛋白酶9, 血管内皮生长因子

Abstract:

Objective： To observe the anti-tumor effect of qingre huatan yiqi sanjie prescription and its influences on serum matrix metalloproteinase-9 （MMP-9） and vascular endothelial growth factor （VEGF） in advanced non-small cell lung cancer （NSCLC）.Methods： 120 patients with advanced NSCLC in our hospital from March 2022 to June 2024 were selected and divided into the control group （routine TP chemotherapy） and the observation group （qingre huatan yiqi sanjie prescription on basis of the control group according to random number table method treatment）， with 60 cases in each group. All patients were treated for 4 cycles （21 d/cycle）. The short-term clinical curative effect， scores of syndromes， levels of serum tumor markers ［carcinoembryonic antigen （CEA）， cytokeratin 19 fragment （CYFRA21-1）， MMP-9 and VEGF］， and adverse reactions were compared between the two groups.Results： The total remission rate of disease in the observation group was higher than that in the control group （P<0.05）. After 4 cycles of treatment， scores of syndromes in the observation group were lower than those in the control group （P<0.05）. After treatment， levels of serum CEA， CYFRA21-1， MMP-9 and VEGF， were lower in both groups than before treatment（P<0.05）， and the decrease of each index in the observation group was better than that in the control group （P<0.05）. The incidence of myelosuppression in the observation group was lower than that in the control group （P<0.05）.Conclusion： Qingre huatan yiqi sanjie prescription has good anti-tumor effect in the treatment of advanced NSCLC， which can effectively improve TCM syndromes scores， reduce serum MMP-9 and VEGF levels， and alleviate adverse reactions of chemotherapy.

Key words: Advanced non-small cell lung cancer； , Qingre huatan yiqi sanjie prescription； , Anti-tumor； , Matrix metalloproteinase-9； , Vascular endothelial growth factor